Published in

American Society for Clinical Investigation, Journal of Clinical Investigation, 1(124), p. 47-55, 2014

DOI: 10.1172/jci69737

Links

Tools

Export citation

Search in Google Scholar

Predicting response to epigenetic therapy

Journal article published in 2014 by Marianne B. Treppendahl, Lasse S. Kristensen, Kirsten Grønbæk ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Drugs targeting the epigenome are new promising cancer treatment modalities; however, not all patients receive the same benefit from these drugs. In contrast to conventional chemotherapy, responses may take several months after the initiation of treatment to occur. Accordingly, identification of good pretreatment predictors of response is of great value. Many clinical parameters and molecular targets have been tested in preclinical and clinical studies with varying results, leaving room for optimization. Here we provide an overview of markers that may predict the efficacy of FDA- and EMA-approved epigenetic drugs.